SCHEMBL3490963

SCHEMBL3490963

Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NCc1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
LMNA P02545 3/20 0.50
GAA P10253 1/20 0.50
RECQL P46063 1/20 0.50
ACLY P53396 1/20 0.48
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
NR3C1 P04150 5/20 0.45
NR3C2 P08235 5/20 0.45
PGR P06401 2/20 0.44
CYP3A4 P08684 3/20 0.44
PLA2G1B P04054 1/20 0.44
CYP2D6 P10635 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491958 0.88 KMT2A (0.54) KMT2AMEN1LMNAALDH1A1HPGD
SCHEMBL3490784 0.85 HPGD (0.47) KMT2AMEN1LMNAACLYL3MBTL1
SCHEMBL3488988 0.85 MEN1 (0.50) KMT2AMEN1GAAACLYALDH1A1
SCHEMBL9272679 0.84 NR3C1 (0.48) KMT2AMEN1LMNAACLYALDH1A1
SCHEMBL3490906 0.82 CA2 (0.53) KMT2AMEN1NR3C1NR3C2PGR
SCHEMBL3489252 0.81 MEN1 (0.54) KMT2AMEN1LMNAGAANR3C1
SCHEMBL3491178 0.81 LMNA (0.52) KMT2AMEN1LMNACYP1A2L3MBTL1
SCHEMBL3488511 0.81 CA12 (0.52) KMT2AMEN1LMNACYP2C19L3MBTL1
SCHEMBL3488618 0.79 NSD2 (0.50) KMT2AMEN1LMNAACLYALDH1A1
SCHEMBL3490289 0.79 CYP19A1 (0.47) KMT2ALMNAACLYNR3C1NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D KMT2A 4557/4885MEN1 4200/4885LMNA 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.